We conclude the immunization schedule for our new candidate vaccine against human brucellosis—tetravalent vaccine formulation based on recombinant influenza A virus subtype H5N1 expressing Brucella Omp16, L7/L12, Omp19 and SOD in prime-boost intranasal immunization mode at immunization dose of 106 EID50. Here, SOD1 is linked to brucellosis.